Following anterior cruciate ligament (ACL) injury, quadriceps muscle atrophy persists despite rehabilitation, leading to loss of lower limb strength, osteoarthritis, poor knee joint health and reduced quality of life. However, the molecular mechanisms responsible for these deficits in hypertrophic adaptations within the quadriceps muscle following ACL injury and reconstruction are poorly understood. While resistance exercise training stimulates skeletal muscle hypertrophy, attenuation of these hypertrophic pathways can hinder rehabilitation following ACL injury and reconstruction, and ultimately lead to skeletal muscle atrophy that persists beyond ACL reconstruction, similar to disuse atrophy. Numerous studies have documented beneficial roles of nutritional support, including nutritional supplementation, in maintaining and/or increasing muscle mass. There are three main mechanisms by which nutritional supplementation may attenuate muscle atrophy and promote hypertrophy: (1) by directly affecting muscle protein synthetic machinery; (2) indirectly increasing an individual’s ability to work harder; and/or (3) directly affecting satellite cell proliferation and differentiation. We propose that nutritional support may enhance rehabilitative responses to exercise training and positively impact molecular machinery underlying muscle hypertrophy. As one of the fastest growing knee injuries worldwide, a better understanding of the potential mechanisms involved in quadriceps muscle deficits following ACL injury and reconstruction, and potential benefits of nutritional support, are required to help restore quadriceps muscle mass and/or strength. This review discusses our current understanding of the molecular mechanisms involved in muscle hypertrophy and disuse atrophy, and how nutritional supplements may leverage these pathways to maximise recovery from ACL injury and reconstruction.
ExtractMiriam Smith The ‘right to silence’ and ‘privilege against self-incrimination’ are distinct but related concepts. Lord Mustill stated in R v Director of Serious Fraud Office, ex parte Smith: This expression [the right to silence] arouses strong but unfocused feelings. In truth it does not denote any single right, but rather refers to a disparate group of immunities, which differ in nature, origin, incidence and importance, and also as to the extent to which they have already been encroached upon by statute. The rights to silence and not to incriminate oneself have long been essential and fundamental elements of the criminal justice system in England and Wales. However, they are not absolute rights. Just as with other areas of criminal law and procedure, Article 6 has had a significant influence on the precise nature and scope of these rights and principles and their development in domestic law. Whilst the twin...
ExtractMary Prior KC Miriam Smith In recent years there has been a drive by Parliament and the criminal courts to ensure that vulnerable witnesses are not subjected to unnecessary trauma while they are involved in the criminal justice system. It is arguable that there has been a greater emphasis on the rights of vulnerable witnesses than on vulnerable defendants giving evidence. The right to a fair trial is enshrined in the law of England and Wales though Article 6 (see Chapter 24) , the common law and statute. Article 6 is engaged when steps are taken to assist witnesses in a way which may be argued to interfere with the rights of defendants and when defendants seek assistance in the forensic process to ensure fairness. In this chapter the relevant measures available to assist vulnerable witnesses are considered generally, with human rights commentary overlaid, so that the commentary may be...
11 July 2026 in Scandinavian Journal of Medicine & Science in Sports
Quadriceps muscle deficits following anterior cruciate ligament (ACL) injury can persist years beyond reconstruction (ACLR), but the underlying molecular mechanisms remain largely unexplored. This study investigated whether persistent muscle deficits following ACLR are associated with defects in hypertrophic signaling pathways in response to acute resistance exercise. Twelve participants (7 females, 5 males; age 26.7 ± 4.1 years; 2.6 ± 1.5 years post‐ACL injury) underwent MRI scanning and one‐repetition maximum (1RM) testing to determine muscle volume and unilateral leg‐press strength in the ACLR versus contralateral control leg. Following a standardized meal and overnight fast, participants performed unilateral leg‐press resistance exercise (6 sets of 8 repetitions at 80% 1RM). Vastus lateralis (VL) muscle biopsies were collected from both legs at rest and immediately post‐exercise. Immunoblotting assessed phosphorylation status and total protein content of hypertrophic signaling proteins (e.g., mTORC1 pathway). Total knee extensor muscle volume (7.5% deficit; p = 0.037), VL (7.7% deficit; p = 0.031), and rectus femoris (5.8% deficit; p = 0.022) muscle volumes were decreased in the ACLR versus contralateral control leg. Knee extensor ( R2 = 0.37; p = 0.036) and VL ( R2 = 0.36; p = 0.038) deficits correlated with increased time since injury, with no associated unilateral leg press 1RM strength difference between legs ( p = 0.192). Despite main effects of exercise observed for mTORC1 pathway signaling proteins (i.e., decreased p‐TSC2 Thr1462; p = 0.002 and p‐4E‐BP1 Thr37/46; p < 0.0001, and increased p‐S6 Ser240/244; p = 0.032), no between‐leg differences in mTORC1 signaling were detected at rest or immediately post‐exercise under the specific experimental conditions tested. In conclusion, persistent muscle volume deficits following ACLR were less pronounced with increased time since injury but were not associated with detectable differences between legs in unilateral leg‐press strength. The lack of detectable between‐leg differences in vastus lateralis mTORC1 signaling warrants further investigation at timepoints closer to ACLR and/or later post‐exercise. Trial Registration: This trial was prospectively registered at the Australian New Zealand Clinical Trials Registry (ANZCTR; trial registration number 12622001166763)